Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 138 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Chemotherapy Side Effects Clear all

Conditions: Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: amifostine trihydrate, cisplatin, gemcitabine hydrochloride; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Cancer
Interventions: Interview, Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Capsaicin Dermal Patch; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: West Hollywood, California • New York, New York • Portland, Oregon

Conditions: Cardiac Toxicity, Malignant Neoplasm, Breast Cancer
Interventions: Magnetic resonance imaging, Physical Activity, Healthy Living, Cardiopulmonary Exercise Testing (CPET), Questionnaire Administration; Procedure · Other · Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Richmond, Virginia

Conditions: Urothelial Carcinoma
Interventions: Livmoniplimab, Budigalimab, Docetaxel, Paclitaxel, Gemcitabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Springdale, Arkansas • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Interventions: filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation; Procedure · Biological · Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 2
States / cities: Indianapolis, Indiana • Boston, Massachusetts

Conditions: Cancer
Interventions: Not listed
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions: amifostine trihydrate, cisplatin, etoposide, radiation therapy; Drug · Radiation
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Childhood Cancer
Interventions: Cardiac 3D MRI; Procedure
Lead sponsor: Majd Makhoul; Other
Eligibility: 8 Years to 26 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Lexington, Kentucky

Conditions: Cancer
Interventions: Shengbai Oral Formula, Inactive Placebo; Dietary Supplement · Other
Lead sponsor: Sutter Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Oakland, California

Conditions: Breast Cancer, Cardiac Toxicity
Interventions: management of therapy complications; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 105
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 19
States / cities: La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more

Conditions: Neoplasms, Diarrhea
Interventions: Sandostatin LAR Depot; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 34
States / cities: Burbank, California • Concord, California • Fountain Valley, California + 31 more

Conditions: Breast Cancer, Chemotherapy-Related Cognitive Impairment
Interventions: Individualized Piano Keyboard Instruction; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions: dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis; Drug · Biological · Procedure + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases, Shingles
Interventions: Capsaicin Dermal Patch; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 28
States / cities: Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more

Conditions: Breast Cancer, Cardiotoxicity, Cardiovascular Diseases
Interventions: High Intensity Interval Exercise, Moderate Intensity Walking; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions: Chinese herbs, cyclophosphamide, doxorubicin hydrochloride, adjuvant therapy; Dietary Supplement · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hand Foot Syndrome, Palmar Plantar Erythrodysesthesia
Interventions: sildenafil citrate; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Mucositis Oral, Head and Neck Cancer
Interventions: MucoLox, Sodium Bicarbonate; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Prevention of Chemotherapy-induced Myelosuppression
Interventions: ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2); Drug
Lead sponsor: Aileron Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 5
States / cities: Tamarac, Florida • Huntersville, North Carolina • Wilson, North Carolina + 2 more

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
Interventions: amifostine trihydrate, cytarabine, mitoxantrone hydrochloride; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 4
States / cities: Chicago, Illinois • Kankakee, Illinois

Conditions: Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: amifostine trihydrate; Drug
Lead sponsor: Rush North Shore Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: Skokie, Illinois

Conditions: Lung Cancer, Head and Neck Cancer, Hearing Loss, Ototoxicity, Tinnitus, Neuropathy
Interventions: SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose, Placebo; Drug
Lead sponsor: Sound Pharmaceuticals, Incorporated; Industry
Eligibility: 19 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Chemotherapy and Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

Chemotherapy-Related Toxicities In Ovarian Cancer Patients

Pilot Study of High-Concentration Capsaicin Patches in the Treatment of Painful HIV-Associated Neuropathy

MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Detection of Chemotherapy Induced Cardiotoxicity

Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer

Cardiac 3D MRI in Pediatric Cancer Patients

A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

Individualized Piano Instruction (IPI) for Improving Cognition in Breast Cancer Survivors.

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

NGX-4010 for the Treatment of Postherpetic Neuralgia

The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies

Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer

Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil

MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

Amifostine in Treating Patients With Cancer Who Have Neurological Changes Caused by Chemotherapy

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss